Head-To-Head Comparison: NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)

Cannlabs (OTCMKTS:CANL) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Volatility & Risk

Cannlabs has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cannlabs and NeuroOne Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannlabs	0	0	0	0	0.00
NeuroOne Medical Technologies	1	0	2	1	2.75

NeuroOne Medical Technologies has a consensus target price of $2.23, suggesting a potential upside of 158.12%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Cannlabs.

Valuation and Earnings

This table compares Cannlabs and NeuroOne Medical Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannlabs	N/A	N/A	N/A	N/A	N/A
NeuroOne Medical Technologies	$12.10 million	3.59	-$3.61 million	($0.08)	-10.78

Cannlabs has higher earnings, but lower revenue than NeuroOne Medical Technologies.

Insider & Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 8.9% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Cannlabs and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cannlabs	N/A	N/A	N/A
NeuroOne Medical Technologies	-29.81%	-74.69%	-44.31%

Summary

NeuroOne Medical Technologies beats Cannlabs on 7 of the 11 factors compared between the two stocks.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.